Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

NCT01225146 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
8
Enrollment
OTHER
Sponsor class

Stopped The collaborator, Genentech, stopped supplying the study drug to the site.

Conditions

Interventions

Sponsor

David M. Brown, M.D.

Collaborators